OSI-027 TROMETHAMINE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H22N6O3.C4H11NO3
Molecular Weight	527.5728
Optical Activity	NONE
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(CO)(CO)CO.COC1=CC=CC2=C1NC(=C2)C3=C4N(N=CN=C4N)C(=N3)[C@H]5CC[C@@H](CC5)C(O)=O

InChI

InChIKey=YMQRKUUPKVIYHX-GJTSMBTKSA-N

InChI=1S/C21H22N6O3.C4H11NO3/c1-30-15-4-2-3-13-9-14(25-16(13)15)17-18-19(22)23-10-24-27(18)20(26-17)11-5-7-12(8-6-11)21(28)29;5-4(1-6,2-7)3-8/h2-4,9-12,25H,5-8H2,1H3,(H,28,29)(H2,22,23,24);6-8H,1-3,5H2/t11-,12-;

HIDE SMILES / InChI

Molecular Formula	C4H11NO3
Molecular Weight	121.135
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C21H22N6O3
Molecular Weight	406.4378
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26213847 | https://www.ncbi.nlm.nih.gov/pubmed/26284306

OSI-027 is an orally bioavailable mammalian inhibitor of mTOR kinase and has antineoplastic activity. OSI-027 binds to and inhibits of the catalytic site of mTOR, which is a central part of two protein complexes, mTORC1 and mTORC2, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. OSI-027 is in phase I clinical trial for the investigation on patients with advanced solid tumors or lymphoma.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Mammalian target of Rapamycin (mTORC1) 23 Target ID: CHEMBL2221341 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21673091	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Lymphoma 58 Sources: https://clinicaltrials.gov/ct2/show/NCT00698243	Primary		Phase I 428	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
11007 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27002938	160 mg 1 times / day multiple, oral dose: 160 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OSI-027 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8780 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27002938	240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered:	OSI-027 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9329 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27002938	160 mg 1 times / day single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	OSI-027 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1110 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27002938	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OSI-027 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3040 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27002938	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	OSI-027 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
105663 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27002938	160 mg 1 times / day multiple, oral dose: 160 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OSI-027 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
125278 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27002938	240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered:	OSI-027 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
131223 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27002938	160 mg 1 times / day single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	OSI-027 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
17246 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27002938	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OSI-027 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
46250 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27002938	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	OSI-027 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
11.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27002938	160 mg 1 times / day multiple, oral dose: 160 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OSI-027 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27002938	240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered:	OSI-027 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27002938	160 mg 1 times / day single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	OSI-027 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27002938	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	OSI-027 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
AK Scientific	2616AH	https://aksci.com/item_detail.php?cat=2616AH
AK Scientific	X7443	https://aksci.com/item_detail.php?cat=X7443
BLD Pharm	BD306064	http://www.bldpharm.com/search/Search.html?keyword=BD306064
Selleck Chemicals	S2624	http://www.selleckchem.com/search.html?searchDTO.searchParam=S2624
Toronto Research Chemicals	D226850	https://www.trc-canada.com/product-detail/?CatNum=D226850
eMolecules	300606980	https://orderbb.emolecules.com/search/#?query=300606980
eMolecules	44696697	https://orderbb.emolecules.com/search/#?query=44696697
eMolecules	68829805	https://orderbb.emolecules.com/search/#?query=68829805

PubMed

Title	Date	PubMed
Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.	2011 Mar 10	21322566

Patents

Sample Use Guides

In Vivo Use Guide

30 mg per day, once daily

Route of Administration: Oral

In Vitro Use Guide

OSI-027 downregulated multidrug resistance (MDR)-1, which has been implicated in chemotherapy resistance in pancreatic ductal adenocarcinoma (PDAC) cells and enhanced apoptosis induced by gemcitabine in the three PDAC cell lines. Human PDAC cell lines (Panc-1, BxPC-3, CFPAC-1) were plated at a density of 3000 cells per well in 96-well plates and the media was removed and replaced by serum free media. 24 hours later the serum free media was replaced by complete media with the addition of OSI-027 at concentration 1.25, 2.5, 5, 10, 20, 40, and 80 μM for at 24, 48, and 72 hours.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 19:05:11 GMT 2023` Edited by `admin` on `Sat Dec 16 19:05:11 GMT 2023`
Record UNII	3Z35AM5LYU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OSI-027 TROMETHAMINE

Common Name

English

OSI-027 TROMETHAMINE SALT

Common Name

English

CYCLOHEXANECARBOXYLIC ACID, 4-(4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO(5,1-F)(1,2,4)TRIAZIN-7-YL)-, TRANS-, COMPD. WITH 2-AMINO-2-(HYDROXYMETHYL)-1,3-PROPANEDIOL (1:1)

Systematic Name

English

CERC-006 TROMETHAMINE

Code

English

AEVI-006 TROMETHAMINE

Code

English

Code System Code Type Description

FDA UNII

3Z35AM5LYU

Created by admin on Sat Dec 16 19:05:11 GMT 2023 , Edited by admin on Sat Dec 16 19:05:11 GMT 2023

PRIMARY

Related Record Type Details


					25MKH1SZ0M

OSI-027

PARENT -> SALT/SOLVATE

Amount:

Related Record Type Details


					25MKH1SZ0M

OSI-027

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26213847 | https://www.ncbi.nlm.nih.gov/pubmed/26284306

Originator

Approval Year

Targets

Conditions

Approved Use

Cmax

AUC

T1/2

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26213847 | https://www.ncbi.nlm.nih.gov/pubmed/26284306

C_max

T_1/2